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Abstract
Background: The purpose of this study was to investigate the therapeutic efficacy of intravenously administered
immunoselected STRO-3 + mesenchymal precursor cells (MPCs) on clinical scores, joint pathology and cytokine
production in an ovine model of monoarthritis.
Methods: Monoarthritis was established in 16 adult merino sheep by administration of bovine type II collagen into
the left hock joint following initial sensitization to this antigen. After 24 h, sheep were administered either 150
million allogeneic ovine MPCs (n = 8) or saline (n = 8) intravenously (IV). Lameness, joint swelling and pain were
monitored and blood samples for leukocytes and cytokine levels were collected at intervals following arthritis
induction. Animals were necropsied 14 days after arthritis induction and gross and histopathological evaluations
were undertaken on tissues from the arthritic (left) and contralateral (right) joints.
Results: MPC-treated sheep demonstrated significantly reduced clinical signs of lameness, joint pain and swelling
compared with saline controls. They also showed decreased cartilage erosions, synovial stromal cell activation and
angiogenesis. This was accompanied by decreased infiltration of the synovial tissues by CD4+ lymphocytes and CD14+
monocytes/macrophages. Over the 3 days following joint arthropathy induction, the numbers of neutrophils circulating in
the blood and plasma concentrations of activin A were significantly reduced in animals administered MPCs.
Conclusions: The results of this study have demonstrated the capacity of IV-administered MPCs to mitigate the clinical
signs and some of the inflammatory mediators responsible for joint tissue destruction in a large animal model of
monoarthritis.
Keywords: Animal model, Collagen-induced arthritis, Mesenchymal stem cells, Neutrophils
Background
Neutrophils play an important role in the initiation and
progression of rheumatoid arthritis (RA) where they ac-
cumulate in large numbers within the synovium and
synovial fluid (SF) of the joint affected joints [1–5].
Apart from their potent cytotoxic properties they also
contribute to cytokine and chemokine release/activation
and regulate immune responses through cell–cell inter-
actions [3–5]. Recent research has also identified their
ability to participate in autoimmune diseases via the pro-
duction of neutrophil extracellular traps (Nets) [5]. Sub-
sequent to the influx of neutrophils, there is an influx of
monocytes that mature into tissue macrophages. Both
cell types can play both pro- and anti-inflammatory roles
[6]. In the autoimmune condition, rheumatoid arthritis,
the prominent T cell infiltrate demonstrates that these
cells are also key participants [7].
Murine models of arthritis have been widely used to iden-
tify many of the pathogenic pathways implicated in
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inflammation and joint tissue destruction in RA [4, 8–11],
however, their high metabolic rate, low body mass and
short lifecycle has resulted in some mechanistic discrepan-
cies to human RA, particularly in their response to treat-
ment with anti-arthritis therapeutic agents [11, 12].
The ovine model of collagen-induced arthritis (CIA)
produces a reproducible model of inflammatory arthritis
in hock joints over 2 weeks and this can be used to evalu-
ate clinical signs of lameness, synovial fluid and synovial
membrane changes and cartilage erosion through the
course of the inflammatory response [13–15]. The major
advantages of a large animal model such as the sheep is
that the anatomy of the joints (in terms of tissue thick-
ness) and the load-bearing stresses transmitted across the
peripheral joints are comparable to the human. Since bio-
mechanical factors are important contributors to joint tis-
sue homeostasis and failure, we consider that assessment
of lameness in this species is more relevant to the human
disease than in rodents. Moreover, the ovine CIA model
exhibits pain and swelling of the affected joints shortly
after the induction of arthritis, followed by the develop-
ment of a mild but chronic arthritis. From a practical
standpoint, the ovine CIA model also has advantages over
rodent models, with respect to the ease of access to target
joints for intra-articular injections, collection of multiple
fluid samples and the ability to cannulate the lymphatic
ducts in order to monitor the cell populations exiting the
joint [16].
Adult mesenchymal stem cells (MSCs) are able to dif-
ferentiate into cells of the mesodermal lineage (including
bone, cartilage and tendons) and were first developed
therapeutically with a view to utilising their regenerative
capacity [17]. However, a large number of studies have
now reported the capacity of these cells to modulate im-
mune system functions both in vivo and in vitro [18]. A
limited number of studies of MSC therapy in rodent
models of collagen-induced arthritis (CIA) have been
published, reporting mixed therapeutic and non-
therapeutic effects [19–24]. Differences in MSC source,
isolation and culture techniques, dose, route and timing
of administration may all account for the variable out-
comes observed.
Nevertheless, several of these studies have reported
promising therapeutic effects including suppression of T
cell activation and reductions in pro-inflammatory cyto-
kine production [19, 20, 22, 23]. Mesenchymal precursor
cells (MPCs) are a restricted subset of MSCs that, when
STRO-1 or STRO-3 immunoselected, demonstrate in-
creased clonogenic, developmental and proliferative cap-
acity compared with unfractionated MSCs [25].
In the present study, we utilized the ovine CIA model
of monoarthritis to test the hypothesis that the intraven-
ous administration of a single dose of 150 million allo-
geneic MPCs would reduce the clinical signs of arthritis,
ameliorate the systemic elevation of leukocytes, particu-
larly neutrophils, diminish the infiltration of inflamma-
tory cells, synovial proliferation, stromal activation and
cartilage destruction in the affected joints.
Methods
Animals
A total of 16 2-year-old female merino sheep were ob-
tained from a local supplier and were acclimatised to
their housing for at least 2 weeks before experiments
commenced. The Animal Ethics Committee of the Uni-
versity of Melbourne approved all experimental animal
procedures and sample collections (reference number:
1212422.3). One sheep from the MPC-treated group was
excluded from the study at necropsy due to concurrent
inflammatory disease of the lung that was unrelated to
the study, giving final groups of eight control sheep and
seven MPC-treated sheep.
Arthritis induction
The ovine arthritis model was based on the sensitization
of the animals to bovine collagen type II (BCII; [13, 26]).
The sheep were allocated randomly into two groups. BCII
was refined from bovine tracheal cartilage based on
Miller’s method [27] using pepsin digestion (3200–4500
units/mg protein; Sigma-Aldrich, St. Louis, MO, USA)
and fractional salt precipitation as we have described pre-
viously [13]. The purity of the preparation was confirmed
by biochemical analysis for the hydroxyproline content
and Western Blotting using a commercial sample of bo-
vine tracheal cartilage type II collagen (Sigma-Aldrich). A
single batch was then lyophilised and stored at -20 °C and
used for all animals. Lyophilised BCII was dissolved asep-
tically in 50 mM acetic acid at 4 °C and reconstituted ali-
quots were stored at -80 °C. The dissolved collagen was
emulsified with the Freund’s Complete Adjuvant (FCA)
(Sigma-Aldrich) by mixing equal volumes using a Norm-
ject Luer-lock syringe (Henk Sass Wolf, Tuttlingen,
Germany) connected to a second Normject Luer-lock syr-
inge with a Popper micro-emulsifying needle. Sheep were
sensitized to collagen on day 0 by subcutaneous injection
in the flanks with an emulsion of 5 mg/ml BCII in
Freund’s Complete Adjuvant (FCA). An immunization
boost was given on day 14 by subcutaneous (SC) injection
of 5 mg/ml BCII in Freund’s Incomplete Adjuvant (Sigma-
Aldrich). Two weeks later (day 28), arthritis was induced
by intra-articular (IA) injection of 100 μg BCII dissolved
in 0.5 ml saline into the left hock (tibio-tarsal) joint. Both
groups of sheep had arthritis induced in the left hock.
Mesenchymal precursor cell treatment
Allogeneic, STRO-3+ ovine mesenchymal precursor cells
(MPC) were provided by Mesoblast Ltd (Melbourne, VIC,
Australia) cryopreserved in ampoules containing 30 million
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MPC/ml in 4 ml ProFreeze®/DMSO/αMEM. Ovine STRO-
3+ MPC were immunoselected and expanded in culture to
passage P5 as previously described [28, 29].
Following thawing, cell counting (using a Neubauer
haemocytometer), and determination of viability (trypan
blue exclusion method), 150 million MPC were injected
into a sterile 0.9% saline drip bag (100 ml) immediately
prior to administration into the sheep. The cells were
then administered systemically over 30 minutes via a
pre-placed jugular intravenous (IV) catheter. A filter was
placed in the giving set to trap any cell clumps. Control
sheep received the equivalent volume of saline. Treat-
ments were administered 1 day following the intra-
articular BCII injection and arthritis induction.
Clinical lameness scoring
Clinical lameness was assessed using a semi-quantitative
scoring system, as described previously [14]. A 6-point
(0–5) scale was used for lameness, and 4-point (0–3)
scales were used for joint swelling and pain elicited on
flexion of the hock. The lameness assessment included the
parameters of behaviour, standing posture and gait. The
clinical signs for joint swelling were assessed as 0 (none
detectable), 1 (barely detectable, but present), 2 (clearly
discernible swelling on palpitation) and 3 (very marked
joint swelling). Pain on flexion was assessed as 0 (none
elicited), 1 (slight discomfort on strong flexion), 2 (clear
discomfort with strong flexion) and 3 (severe discomfort
even with slight flexion and sheep very reluctant to flex
the joint). Lameness, joint swelling and pain on flexion
were assessed weekly until the IA collagen injections (day
28) and then on days 29, 30, 31, 32, 34, 36, and 42 after
the IA injection. All investigators who participated
remained blinded to the treatment group allocation.
Sample collection
Blood was collected from the jugular vein weekly until
day 28, then daily for 3 days following arthritis induc-
tion, then every 2–3 days thereafter.
Sheep were killed 2 weeks after the induction of
arthritis (on day 42), and post mortem examinations
were performed. Synovial membranes (SM), cartilage
from the articular surface of the talus bone, and syn-
ovial fluid were collected at necropsy from all ani-
mals. Gross findings were recorded for each tissue
and SM were collected from the dorsal region of the
left and right joints. Part of the SM was fixed in 10%
buffered formalin and sent to Gribbles Veterinary La-
boratories, Melbourne, VIC, Australia for routine pro-
cessing and staining (haematoxylin and eosin) for
light microscopy. The other half of the SM was
placed in OCT compound (Tissue-Tek, Sakura Fine-
tek, Torrance, CA, USA), snap frozen in liquid nitro-
gen and stored at -80 °C for immunohistology.
Blood and synovial fluid cytology
Total leukocyte numbers in blood and SF were obtained
using an automated cell counter (Coulter Particle Coun-
ter, Model Z1; Beckman Coulter, Indianapolis, IN, USA)
while the differential cell count was determined on
Giemsa-stained blood smears or SF cytospots. The dif-
ferential cell count was performed counting a minimum
of 200 cells under a light microscope. Results are pre-
sented as number of cells/ml of blood or SF.
Cytokine assays
The concentrations of interleukin (IL)-17A and activin
A were measured in plasma and synovial fluid by
sandwich enzyme-linked immunosorbent assay
(ELISA). The concentration of IL-17A in plasma and
SF was estimated using Bovine IL-17A VetSet™ ELISA
Development Kit (Kingfisher Biotech, Inc, Saint Paul,
MN, USA) according to the manufacturer’s instruc-
tions. The concentration of activin A in plasma and
SF was estimated using Quantikine ELISA ready kits
(R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions. IL-10 was estimated
using anti-bovine IL-10 (cc318, Bio-Rad Laboratories,
Hercules, CA, USA) and biotinylated anti-bovine IL-
10 (cc320, Bio-Rad Laboratories) followed by
ExtrAvidin-HRP (Sigma-Aldrich). The standard was
recombinant ovine IL-10, produced as described pre-
viously [30]. Interferon (IFN)-γ was estimated using
anti-bovine IFN-γ mAb (cc330, Bio-Rad Laboratories)
and biotinylated anti-bovine IFN-γ mAb (cc302, Bio-
Rad Laboratories) followed by ExtrAvidin-HRP
(Sigma-Aldrich). The standard was recombinant IFN-
γ (23000-BG, R&D Systems). All assays were
developed with TMB substrate (Life Technologies,
Carlsbad, CA, USA).
Macroscopic scoring of articular cartilage from hock joints
The cartilage on the surface of the talus was assessed
using a 5-point scale based on the Osteoarthritis Re-
search Society International (OARSI) recommendations
for macroscopic scoring of cartilage pathology [31], but
simplified because the primary cartilage injuries were
confined to the central trochlear groove of the talus, ra-
ther than the whole joint surface as we have described
previously [14]. The scheme used was: normal cartilage
surface = 0; roughened cartilage surface but not deep or
extensive fissuring = 1; clear fibrillation and fissuring of
surface = 2; full-depth small erosion confined to troch-
lear groove = 3; full-depth erosions which extended out-
side the trochlear groove to the adjacent condyles = 4.
The mean of the values from two blinded independent
observers were pooled for each treatment group.
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Histopathological scoring of synovial tissues from hock joints
The scoring system developed for this ovine CIA
model was a composite of those used for humans
with modifications for ruminants [31–34], and has
been described previously [14]. The scoring system
assessed three parameters of the synovium; namely
intimal hyperplasia, stromal activation and inflamma-
tory infiltrate (scores from 0 to 3) and the final score
was a total of these three scores, with a maximal
score of 9 points. For consistency, synovial intimal
hyperplasia was specifically evaluated at the predom-
inant cell depth [33]. The synovial intima ranged
from normal (1–3 cells; 0 points) to moderate diffuse
hyperplasia (>6 cells thick in multiple areas; 3 points).
Synovial stromal activation and inflammatory infiltrate
were based upon those areas with the greatest alter-
ations [35]. The degree of activation ranged from
none (0 points) to marked activation with chronic
oedema, marked fibrosis and cellularity, including
endothelial cells and histiocytes (3 points). Synovial
inflammatory infiltration could vary from absence of
inflammation (0 points) to marked inflammatory infil-
trate, which could include lymphocytes, plasma cells
and histiocytes, seen as large aggregations of cells
within the synovial stroma, the synovial intima and in
a perivascular location (3 points). Large areas of ne-
crosis often accompanied severe inflammation. Each
parameter was observed at low power, before evalu-
ation at high power (×40 objectives). The pathological
changes were scored by two blinded observers and if
their scores differed by 2 or more points, the sections
were examined by a third blinded observer.
Immunohistochemical staining of synovial tissues from
hock joints
Frozen sections of SM from the dorsal region of the arth-
ritic and contralateral hock joints were acetone-fixed and
stained by indirect immunohistochemistry. The primary
monoclonal antibodies (mAbs) used were specific for CD4
(44-38), CD8 (38-65) [36] and γδ TCR (86D-127) [37] and
were also obtained from A/Prof. Scheerlinck (Centre for
Animal Biotechnology). B lymphocytes were identified
using mAb specific for CD79acy (HM57, Dako, Glostrup,
Denmark) and monocytes and macrophages were identified
using mAb specific for CD14 (M-M9, VMRD, Pullman,
WA, Australia). Monoclonal antibody specific for Ki-67
(MIB-1, Dako) was used to detect cells in active phases of
the cell cycle while angiogenesis was detected using mAb
specific for von Willebrand factor (vWF) (Dako) on endo-
thelial cells. In all cases, isotype-matched non-specific anti-
bodies were used as negative controls. The primary
antibodies were detected with a rabbit anti-mouse HRP
(Dako) and DAB (Sigma-Aldrich).
Scoring of the immunohistochemically stained tissues
from hock joints
The SM sections stained for mononuclear inflammatory
cell types were scored and assessed on a 7-point scale
(0–6) based on the approximate cell count and/or the
size and the numbers of cell clusters [14]. The criteria
used were: 0 = no cells in the entire section; 1 = < 10
cells in the entire section; 2 = 10–50 cells and/or 1–2
small clusters of cells; 3 = 50–200 cells and/or > 2 small–
medium clusters of cells or numerous cells; 4 = 200–500
cells and/or many small–medium clusters; 5 = 500–1000
cells and/or many medium–large clusters of cells and 6
= > 1000 cells and/or very large clusters of cells. This
system was modified for CD14+ cells, where the cell
numbers were 10-fold greater (i.e. 0 to > 10,000 cells).
The density of blood vessels in the synovium was esti-
mated by counting the average number of vWF-stained
vessels in three microscope fields using a × 4 objective.
Statistical methods
Results are expressed as mean ± SEM unless otherwise
indicated. Data were analysed using GraphPad Prism
statistical software (version 6.0b; GraphPad Software Inc,
La Jolla, CA, USA). Analysis of data between groups at
different time points was performed using two-way
ANOVA with Sidak’s multiple comparison tests. Area
under the curve with respect to increase (AUCI) was
used to compare changes in plasma cytokines where ini-
tial baseline values differed between groups. The AUCI
was calculated by the trapezoid rule using GraphPad
Prism software, starting from day 29 (immediately prior
to MPC or saline administration) and using the value at
that point as the baseline. Endpoint data were evaluated
using Mann-Whitney or Wilcoxon matched-pairs signed
rank tests and statistical significance between groups
was accepted at p < 0.05.
Results
Clinical assessment
Intra-articular administration of collagen caused a mild
to moderate lameness with localised joint swelling and
pain on flexion, which was detectable in all sheep after
24 h (Fig. 1). All signs of lameness and inflammation
then decreased steadily from day 29 to day 42. Lameness
scores were significantly lower in the group treated with
MPC from days 31 to 36 inclusive (Fig. 1A), and there
was a significant overall improvement in lameness for
the MPC treatment group relative to saline controls.
Lameness was decreased to a mean score of 1 by day 34
in the treated group while the untreated group still had
a mean greater than 1 at day 42. For pain on flexion
(Fig. 1B), there was a more rapid improvement in the
MPC-treated group compared to the saline group with
almost no pain by day 42. The pain scores were
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significantly improved between days 31 and 36 inclusive.
Figure 1C shows the results of swelling in the hock joint.
Although the swelling was mild, the scores for swelling
were significantly lower for days 31 and 34 in the MPC-
treated group. When combining all three clinical
parameters (Fig. 1D), there were again significant im-
provements in the scores between days 31 and 36.
Total and differential white cell counts (WCC) in blood
There was a significant increase in the total blood
leukocyte count following IA arthritis induction in both
treatment groups (Fig. 2A) and this was attributable pri-
marily to the neutrophil numbers (Fig. 2B). However,
following MPC treatment there was a faster decline in
the number of neutrophils in the blood, with signifi-
cantly lower neutrophil numbers measured for the 2 days
following MPC infusion (Fig. 2A and B). Lymphocyte
and monocyte numbers in blood showed little change
after IA arthritis induction, and treatment had no effect
on their numbers (data not shown).
Total and differential white cell counts in synovial fluid
The total leukocyte count in the SF of arthritic left joints
was significantly higher than in the contralateral right
joints as we have previously reported [14], however the
neutrophil counts were not significantly different between
left and right joints in the MPC-treated sheep. After this
period of time the leukocyte counts had decreased such
that there were no significant differences between the syn-
ovial fluid cell numbers in the left hock joints of treated
versus control sheep. However, there was a moderate
trend to suggest that the numbers of neutrophils in the
synovial fluid of the left hock joints in MPC-treated sheep
(3 ± 1% of total cells) was reduced compared with the
numbers in saline-treated control sheep (21 ± 8% of total
cells; p = 0.09).
Inflammatory markers in blood
Activin A
While the mean plasma activin A levels at individual
time points for the two treatment groups were found
not to be significantly different (due mainly to one sheep
in the control group that had a 10–20-fold higher level
of activin A than other sheep prior to arthritis induction)
analysis of areas under the curve (AUC) for each sheep
did demonstrate significant differences as shown in
Fig. 3. Using this approach, starting from day 29 (imme-
diately prior to MPC or saline administration), indicated
that there was a significant drop in plasma activin A fol-
lowing MPC treatment (38 ± 117 arbitrary units; Fig. 3A)
compared with plasma levels in untreated sheep (378 ±
294 arbitrary units; p = 0.021).
IL-17A
Plasma IL-17A levels decreased over the first 2 days post
treatment in the sheep treated with MPCs. Again, there
Fig. 1 Effect of MPC administration on lameness (A), pain on joint flexion (B) and joint swelling (C) in sheep with CIA in the left hock. Intra-articular
injection of BCII was performed on day 28 and MPC administration on day 29. There was a significant reduction in all measured parameters and the
aggregate score (D) 2 days after MPC treatment. Values were analysed using two-way ANOVA with Sidak’s multiple comparison tests and each point
represents the mean ± SEM of seven to eight sheep with *, **, ***and **** representing p≤ 0.05, 0.01, 0.001 and 0.0001 respectively. MPC mesenchymal
precursor cells
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was variability between individual sheep in the initial
baseline levels of this cytokine in both groups that pre-
cluded statistical significance using the mean values.
However, analysing the area under the curve for IL-17A
plasma levels for each sheep starting from day 29, dem-
onstrated a significant reduction of this cytokine in the
MPC treatment group compared to the saline-injected
group (p = 0.006; Fig. 3B).
Inflammatory markers in synovial fluid
Although there were significantly raised levels of the cy-
tokines activin A, IL-17A and IFN-γ, but not IL-10 in
the synovial fluid of left arthritic joints compared to the
right contralateral joints, no significant changes could be
demonstrated between the saline and MPC treatments
(Fig. 4A-C).
Gross joint pathology
As shown in Fig. 5, at the time of necropsy (day 42), left
hock joints revealed profound pathological changes. These
included joint swelling, gross SM thickening and focal car-
tilage erosion on the articular surface of the talus bone
and distal tibia bones. The magnitude of these changes
were most evident in the left hock joints from the saline-
treated control sheep (Fig. 5A and C) but were less pro-
nounced in the MPC-injected sheep (Fig. 5B and D).
Scoring of cartilage erosions
Cartilage erosions on the articular surface of the talus
bone (Fig. 5A-D) were assessed using a macroscopic
scoring system and MPC treatment was shown to sig-
nificantly reduce cartilage erosion in the arthritic joint
compared to arthritic joints from saline-treated control
sheep (Fig. 6).
Histopathological scoring of synovial tissues from hock
joints
The histopathology scores for synovial tissues, which in-
cluded hyperplasia, stromal activation and inflammatory
cell infiltration are shown in Fig. 7. All parameters differed
significantly between the arthritic and contralateral syn-
ovial tissues within both groups. Treatment with MPC sig-
nificantly reduced the levels of stromal activation,
including lowered fibrosis, cellularity and matrix depos-
ition, in the arthritic left joint compared to the same joint
in the saline-treated controls (p < 0.05).
The reduction in intimal hyperplasia or inflammatory cell
infiltration did not reach statistical significance. The com-
bined total histopathology score also showed a trend to-
wards being lower in the treated group (p = 0.0665; Fig. 7D).
Immunohistochemical studies of the synovial tissues
The inflammatory cell types (CD4+, CD8+ and γδ TCR+ T
cells, B cells, and monocytes/macrophages) examined in
Fig. 2 Effect of MPC administration on total blood leukocyte (A), neutrophil (B), lymphocyte (C) and monocyte (D) counts. Values were analysed
using two-way ANOVA with Sidak’s multiple comparison tests and each point represents the mean ± SEM of seven to eight sheep with *, ** and
*** representing p≤ 0.05, 0.01 and 0.001, respectively. MPC mesenchymal precursor cells
Abdalmula et al. Stem Cell Research & Therapy  (2017) 8:22 Page 6 of 13
the synovial tissues of the arthritic left joints were ob-
served to be more abundant than in the corresponding tis-
sues of the contralateral joints (Fig. 8a-e). Treatment with
MPC significantly reduced the number of CD4+ T cells
and CD14+ monocytes/macrophages (by 40%) in the syno-
vium of MPC-treated sheep compared to the saline-
treated control group (Fig. 8a, e). The other cell subsets
(CD8+ and γδ TCR+ T cells, and CD79a+ B cells) were also
lower in the MPC-injected group, but they were not
statistically different from the saline-treated controls
(Fig. 8b-e). Cells in active phases of the cell cycle, as indi-
cated by Ki-67 expression, were also increased in the
inflamed joints compared to contralateral joints, but
showed no response to MPC treatment (Fig. 8f). There
was, however, a significant reduction of 50% in the num-
ber of blood vessels (as measured by vWF expression) in
the arthritic synovium of MPC-treated sheep compared
with saline-treated controls (Fig. 8g).
Discussion
This study evaluated the acute anti-inflammatory activities
of immunoselected allogeneic STRO-3+ ovine mesenchy-
mal precursor cells (MPCs) in an ovine model of monoar-
thritis and clearly demonstrated an anti-inflammatory
effect of MPCs following IV administration. In rodent col-
lagen arthritis models, where systemic administration of
MSCs has reduced disease severity, this treatment has
been associated with the suppression of T cell activation, a
reduction in serum pro-inflammatory cytokine expression,
and the induction of Foxp3+ regulatory T cells with an im-
munosuppressive phenotype [19, 22, 38]. MPCs are a re-
stricted subset of MSCs, and this is the first study to
demonstrate their effectiveness in a non-rodent, large ani-
mal model of collagen-induced arthritis.
The significant reduction in clinical scores within 4 days
of systemic administration of the MPCs correlated with the
marked decline of plasma neutrophil levels that were in-
creased within 24 hours of arthritis induction. The in-
creased blood neutrophil levels in response to CII
immunisation have been attributed to the induction of IL-8
by IL-6, and the recruitment of neutrophils from the mar-
ginal pool by chemotactic factors including leukotriene B4,
C5aR and FcγRs in sequence [4, 9, 10, 39]. However, in a
parallel study using the same ovine model of CIA but sacri-
ficing the animals 72 days post arthritis induction,
leukocyte populations within synovial fluids were elevated,
[14], but the levels were not altered by MPC treatment.
Presumably, 2 weeks after arthritis induction, most of the
inflammatory changes were restricted to the synovium it-
self, and there was little chemotactic stimulus to promote
migration of neutrophils from synovium into the synovial
fluid. Nevertheless, in the present study there was evidence
to suggest that the numbers of neutrophils in the synovial
fluid of the left hock joints in MPC-treated sheep was re-
duced compared with the numbers in joints of the saline-
treated control sheep. Although SF samples were collected
only at the time of necropsy, sampling at earlier time points
in the study may have revealed differences in the synovial
fluid cellular composition associated with MPC treatment;
however this procedure was excluded from the study proto-
col due to the risk of inducing inflammatory changes within
the joint from repeated joint sampling.
Activated neutrophils have been shown to be a major
source of the inflammatory marker, activin A [40, 41].
Activin A is a member of the transforming growth factor
Fig. 3 Effect of MPC administration on plasma cytokines in sheep with
CIA. Plasma concentrations of activin A (A), and IL-17A (B) were com-
pared between the MPC-treated and control group using two-way
ANOVA with Sidak’s multiple comparison tests. The AUCI for the maximal
responses between days 29 and 36 of activin A (A) and IL-17A (B) were
compared using Mann-Whitney tests. Each point represents the mean ±
SEM for concentrations or mean± SD for AUC of seven to eight sheep
with *and ** representing p≤ 0.05 and 0.01, respectively). MPC
mesenchymal precursor cells
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beta (TGF-β) family, and it is thought to play a major
role in inflammation. It stimulates the production of cy-
tokines and iNOS, and regulates or suppresses TH1 and
TH2 responses [42]. Increases in plasma concentrations
of activin A have been demonstrated in patients suffer-
ing various inflammatory conditions [43]. In particular,
activin A concentrations in the synovial fluid of patients
with gout and rheumatoid arthritis are elevated relative
to those patients with osteoarthritis [44]. In such condi-
tions, it has been suggested that activin A promotes pro-
inflammatory macrophages and induces hyperalgesia,
and that early suppression of activin A in RA might re-
duce pain and joint damage [45]. In the present study,
plasma activin A levels showed a significant increase in
the saline-treated control group, soon after arthritis was
initiated with a peak at day 34, while the sheep adminis-
tered MPC exhibited relatively reduced levels of activin
A. Our findings of lowered activin A levels, reduced
blood neutrophils and lowered signs of pain on flexion
and lameness in the MPC-treated group appears to sup-
port the hypothesis that the reduction of blood neutro-
philia, with subsequent reduction of activin A and other
pro-inflammatory factors, may be an important mechan-
ism by which MPC exert their anti-inflammatory effect.
Plasma IL-17A levels decreased over the first 2 days post
MPC treatment, however the IL-17A levels in blood were
low and rather variable between individual sheep. IL-17A
is a pro-inflammatory cytokine produced primarily by
Th17 cells and γδ-T cells [46]. In gout and many other
inflammatory conditions, assembly of intracellular pattern
recognition receptors (NLRs) into the inflammasome
complex leads to the enzymic activation of IL-1β and IL-
18 into their mature forms, which promotes IL-17 pro-
duction from the above mentioned cells [47]. In the joints
of arthritic patients this cytokine is thought to promote in-
flammatory cell infiltration, bone destruction, and synovial
fibroblastic activity [48–50]. Serum and synovial IL-17A
levels in human RA patients can be significantly higher
compared with normal controls, although IL-17A may not
be present in all RA patients [51, 52].
MPC treatment did not appear to have a marked effect
on cytokine levels in the synovial fluid of arthritic joints
2 weeks after arthritis induction. Activin A, IL-17A and
IFN-γ were all higher in arthritic SF of the saline-treated
sheep than in the contralateral joints, but not altered
significantly in the MPC-treated group. Only IL-17A
showed a possible reduction in SF of MPC-treated
sheep, with no IL-17A detected in five sheep, but the ef-
fect of treatment was unclear due to the presence of two
sheep that had very high levels of IL-17A.
The synovial membrane plays a very important role in
disease pathogenesis in arthritis, with synovitis and erosion
of articular cartilage being key features. The reduced cartil-
age damage evident in MPC-treated sheep is consistent
with an anti-inflammatory mode of action. It is thought
that cartilage damage is initially driven by inflammatory cy-
tokines including IL-17A, IL-1β and tumour necrosis factor
alpha (TNF-α), acting synergistically to induce the
Fig. 4 Effect of MPC administration on SF cytokines in sheep with CIA. Concentrations of activin A (A), IL-17A (B), IFN-γ (C) and IL-10 (D), were
compared between the MPC-treated and the control group using paired Wilcoxon (left versus right) and unpaired Mann-Whitney (saline versus
MPC treatment) tests. Lines represent mean ± SEM of seven to eight sheep and * and ** represent p≤ 0.05 and 0.01, respectively. IFN interferon, IL
interleukin, MPC mesenchymal precursor cells
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production of matrix metalloproteinase proteinases (includ-
ing aggrecanases), which degrade cartilage [53, 54]. Re-
duced levels of stromal activation (fibroblast numbers,
cellularity and matrix deposition) in the arthritic joints of
MPC-treated sheep are important because the synovial
stroma is the major site for inflammatory cell recruitment
and cell activation.
Neutrophils play an important early role inflammatory
arthritis, but in the current acute model they were no
longer present in the synovium in significant numbers
by the time of necropsy 14 days later, and instead lym-
phocytes, monocytes and macrophages were the pre-
dominant inflammatory cell types. MPC treatment 1 day
after arthritis induction appeared to greatly limit the re-
cruitment of CD4+ T cells and CD14+ monocytes and
macrophages (by around 40%) to the synovium. CD4+ T
cells and monocytes/macrophages both play an import-
ant role in the pathophysiology of arthritis. These cells
release a number of chemotactic and other inflammatory
cytokines such as TNF-α that recruit other inflammatory
cells that maintain the arthritic process [55].
While MSC transplantation has been shown to suppress
the proliferation of CD4+ T cells in a mouse model of graft-
versus-host disease [56], it was uncertain whether the find-
ing in the current study reflected reduced proliferation, or
reduced recruitment of cells. Since the number of Ki-67+
cells was similar in saline- and MPC-treated synovium, it is
arguable that reduced cellular recruitment may be a likely
Fig. 5 Effect of MPC treatment on gross joint pathology in the sheep CIA model. Representative photographs of joint swelling and gross
appearance of articular cartilage from the left hock joints of control (A and C) and MPC-treated (B and D) sheep 14 days after the induction of
arthritis, the arthritic left hock joint from the control animal shows more severe erosion of the cartilage on the articular surface of the talus bone
(panel C; arrow) and on the articular surface of the distal tibia, compared to the MPC-treated sheep (panel D). MPC mesenchymal precursor cells
Fig. 6 Effect of MPC treatment on cartilage erosion in the sheep
CIA model. The cartilage on the surface of the talus was
assessed macroscopically using a 5-point scale based on the
OARSI recommendations for macroscopic scoring of cartilage
pathology, as described in the Methods section. Values were compared
between the MPC-treated and the control group using paired Wilcoxon
(left and right) and unpaired Mann-Whitney (saline and MPC treatment)
tests. Lines represent mean ± SEM of seven to eight sheep. ** represents
significant difference; p≤ 0.01. MPC mesenchymal precursor cells
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mechanism. This would be consistent with findings that
MSCs significantly reduce expression of key chemokines
for attracting macrophages (MCP-1) in vitro and in a rat
model of acute traumatic brain injury, with a corresponding
decrease in macrophage infiltration [57, 58].
Hyperplasia of the inflamed synovial tissue is sup-
ported by endothelial proliferation and angiogenesis,
which in long-standing disease may ultimately result
in the formation of an invasive pannus. Angiogenesis
within the synovium was significantly reduced with
MPC treatment in this study. Angiogenesis is a noted
feature of RA and is thought to be associated with
angiogenic chemokines and vascular endothelial
growth factor [59–63]. VEGF is produced by mono-
cytes, macrophages and fibroblasts; and together with
IL-17A stimulates angiogenesis leading to cell recruit-
ment and synovitis development [55, 64]. MSC are
generally thought to increase angiogenesis via the re-
lease of VEGF [65] and naturally occurring MSC in
the synovium of RA patients have been implicated in
this process [66], so the significant reduction in
angiogenesis following MPC treatment in the sheep
model may be a specific effect of the highly purified
MPCs used in this study.
Fig. 7 A Effect of MPC treatment on synovial histopathology in the sheep CIA model. Synovial histopathology scores were determined for
samples from the left hock joints of control and MPC-treated sheep 14 days after the induction of arthritis. The parameters included stromal cell
activation (panel a), intimal hyperplasia (panel b) and inflammatory cell infiltration (panel c), plus a combined total score (panel d). Values were
compared between the MPC-treated and the control group using paired Wilcoxon (left and right) and unpaired Mann-Whitney (saline and MPC
treatment) tests. Lines represent mean ± SEM of seven to eight sheep. * and ** represent significant difference; p≤ 0.05 and p≤ 0.01, respectively.
B Representative histopathological images of synovial membranes from arthritic hock joints following saline (a-c) or MPC (d-f) treatment. Paraffin-
embedded tissues were stained with haematoxylin and eosin. The bars represent 250 μm. MPC mesenchymal precursor cells
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Conclusions
The results of the present study using the ovine model of
inflammatory arthritis have confirmed that a single intra-
venous infusion of 150 million allogeneic MPC per animal
was effective in reducing the clinical signs of arthritis and
gross pathological changes in the arthritic joint. Treatment
also attenuated histopathological changes including syn-
ovial stromal tissue activation, CD4+ T cell and monocyte/
macrophage accumulation in the synovium and synovial
angiogenesis. MPC treatment was associated with
significant decreases in blood neutrophilia and associated
inflammatory biomarkers such as activin A. This study
demonstrates that MPCs were able to profoundly modu-
late the inflammatory cascade in this ovine model of
collagen-induced arthritis, leading to a downregulation of
both local and systemic inflammation. Together, these data
support the potential application of MPCs for the treat-
ment of acute tissue inflammation such as arthritis. It ap-
pears that MPCs have the ability to reduce the early events
in the disease process, which is consistent with current
Fig. 8 A Effect of MPC treatment on the number of inflammatory cells in SMs from sheep with CIA. Lines represent median and interquartile ranges
of seven to eight sheep. Frozen sections were immunostained for CD4 (a), CD8 (b), γδ TCR (c), CD79a (d), CD14 (e) and Ki-67 (f). Blood vessels were
identified by vWF expression (g). The data were compared using paired Wilcoxon (left and right) and unpaired Mann-Whitney (saline and MPC
treatment) tests. Lines represent mean ± SEM of six to eight sheep with * and ** representing p≤ 0.05 and p≤ 0.01, respectively. B Immunohistology of
synovial membranes from arthritic hock joints following saline (left column) or MPC (right column) treatment. The frozen sections were stained with
antibodies to CD4 (a, b), CD8 (c, d), γδTCR (e, f), CD79a for B cells (g, h) and CD14 (i, j). The bars represent 25 μm. MPC mesenchymal precursor cells
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recommendations for early anti-inflammatory intervention
in arthritis [67].
The present studies also highlight the potential of
using MPCs as a novel biological agent for the manage-
ment of human RA. However, additional preclinical and
clinical studies will be clearly required to establish more
precisely the pathways used by MPCs to mediate their
therapeutic effects in RA.
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